Nanoscale Pathogens Treated with Nanomaterial-Like Peptides: A Platform Technology Appropriate for Future Pandemics

Nahhas, Alaa F.; Nahhas, Alrayan F.; Webster, Thomas J

doi:10.2217/nnm-2020-0447

Cited by 13 publications

(10 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, nano-peptide-based-technology is a great smart innovation for modern bio-medicine. More specifically, triggered transformation of nano-peptides, by interaction with stimuli in bio-environments, facilitates opportunities for the development of smart biomaterials that cannot be achieved with traditional molecules ( Nahhas et al, 2021 ). The flexibility in inter-and intramolecular interactions of short peptides creates space for construction of supramolecular nanostructures with diverse applications.…”

Section: Landscape Of Opportunities: Topical Insightsmentioning

confidence: 99%

Smart therapies against global pandemics: A potential of short peptides

et al. 2022

View full text Add to dashboard Cite

BackgroundAs we entered the third year of this pandemic, since the World Health Organisation (WHO) declared in March 2020 the novel coronavirus severe acute respiratory syndrome (SARS-CoV2) outbreak as a global pandemic COVID-19 (COronaVIrus Disease 19), we are still fighting with newer and newer viral mutations. The pandemic has passed the grim milestone of over 6.4 million COVID19 deaths, from more than 550 million reported cases thus far. In fact, more than 15 million people can die by the end of this year. It is highly likely that this pandemic will become endemic, while the full evolutionary potential of coronaviruses has yet to be revealed. The next pandemic is coming. A microbe with features of SARS-Middle East respiratory syndrome (MERS) and SARS-CoV-2 could lead to significantly more catastrophic loss of life. The co-evolution with other viruses should not be neglected. According to the WHO, we should expect diverse zoonotic, outbreakprone microbes, including highly pathogenic strains of influenza, Nipah, Ebola, Zika, or hemorrhagic fever viruses. 'It's an evolutionary certainty that there will be another virus with the potential to be more transmittable and deadly than this one', said Tedros Adhanom Ghebreyesus, director-general of the WHO. On the other hand, in both poor countries and regions of armed conflict, where vaccination is hampered, historic diseases are re-emerging, with migration and displacement influencing transmission risk and limiting control, and raising potential for additional outbreaks. Furthermore, there are other looming terrible threats to humanity as damaging as the bubonic plagues, such as bioterrorism or antibiotic resistant microorganisms. In most cases, both effective prevention and treatment options are limited.

show abstract

Section: Landscape Of Opportunities: Topical Insightsmentioning

confidence: 99%

Smart therapies against global pandemics: A potential of short peptides

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…[22,23] In this context, nanomaterials have also been presented as promising alternative approaches to treat viral infections through different strategies as recently reviewed. [24,25] Consequently, the present study aimed at designing and synthesizing the very first silane-based silica core/shell MIPs using an epitope peptide from the SARS-CoV-2 spike protein as a template, which could then act as a synthetic ACE2 receptor and bind to SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

Plastic Antibodies Mimicking the ACE2 Receptor for Selective Binding of SARS‐CoV‐2 Spike

Batista

Rajpal

Keitel

et al. 2022

Adv Materials Inter

View full text Add to dashboard Cite

Molecular imprinting has proven to be a versatile and simple strategy to obtain selective materials also termed “plastic antibodies” for a wide variety of species, i.e., from ions to macromolecules and viruses. However, to the best of the authors’ knowledge, the development of epitope‐imprinted polymers for selective binding of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is not reported to date. An epitope from the SARS‐CoV‐2 spike protein comprising 17 amino acids is used as a template during the imprinting process. The interactions between the epitope template and organosilane monomers used for the polymer synthesis are predicted via molecular docking simulations. The molecularly imprinted polymer presents a 1.8‐fold higher selectivity against the target epitope compared to non‐imprinted control polymers. Rebinding studies with pseudoviruses containing SARS‐CoV‐2 spike protein demonstrate the superior selectivity of the molecularly imprinted matrices, which mimic the interactions of angiotensin‐converting enzyme 2 receptors from human cells. The obtained results highlight the potential of SARS‐CoV‐2 molecularly imprinted polymers for a variety of applications including chem/biosensing and antiviral delivery.

show abstract

“…However, the structures of those MIPs are full of millions of free substrates which are able to accept the guest drugs for drug delivery applications [12] . In addition, these nano‐sized receptors are applied as the stationary phase for packing of chromatography columns, [13] nano sorbents application, [14] nano actuators, [15] the biosensors, [16] and also the nano‐scale drug delivery systems [17] …”

Section: Introductionmentioning

confidence: 99%

“…[12] In addition, these nano-sized receptors are applied as the stationary phase for packing of chromatography columns, [13] nano sorbents application, [14] nano actuators, [15] the biosensors, [16] and also the nano-scale drug delivery systems. [17] Today, the MIPs are being selected to be used as new candidates for drug delivery system. By applying this newly developed technology, physicians are able to prepare accurate dosages and optimize the release rate of the drugs.…”

Section: Introductionmentioning

confidence: 99%

Application of the Quetiapine Templated Molecular Imprinted Polymer in Its Extraction from Human Blood Plasma; an Experimental and Density Functional Theory Study

et al. 2022

View full text Add to dashboard Cite

In the present project, we have applied a molecular imprinted polymer (MIP) for the solid phase extraction (SPE) of quetiapine residue from human blood plasma. This study aimed to develop a method for determination of the bioavailability of quetiapine as a widely used antipsychotic in the blood serum. The extraction of quetiapine from the plasma was optimized and the loading amount (LA) for its adsorption was determined. Subsequently, a HPLC-UV/VIS method was validated and applied to analyze the concentration of the mentioned drug which was extracted from the blood serum. The results showed that the limit of detection (LOD), and the limit of quantification (LOQ) for the validated MIP-SPE approach were about 0.0172 ng ml À 1 , and 0.0481 ng ml À 1 , respectively. Finally, each of the MIP, and the non-imprinted polymer (NIP), and their complex with the guest drug were designed and optimized by the density functional theory (DFT) approach. Based on our theoretical calculations, the structural properties, as well as the reactivity parameters (the molecular descriptors) were extracted, and debated. The results of the theoretical calculations showed a good agreement with the experimental results. Those results confirmed the favorability of adsorption of the drug by MIP compared to NIP.

show abstract

Nanoscale Pathogens Treated with Nanomaterial-Like Peptides: A Platform Technology Appropriate for Future Pandemics

Cited by 13 publications

References 130 publications

Smart therapies against global pandemics: A potential of short peptides

Smart therapies against global pandemics: A potential of short peptides

Plastic Antibodies Mimicking the ACE2 Receptor for Selective Binding of SARS‐CoV‐2 Spike

Application of the Quetiapine Templated Molecular Imprinted Polymer in Its Extraction from Human Blood Plasma; an Experimental and Density Functional Theory Study

Contact Info

Product

Resources

About